Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2016 - 2025)

Collegium Pharmaceutical has reported Gains from Investment Securities over the past 10 years, most recently at -$19000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$19000.0 for Q4 2025, up 99.35% from a year ago — trailing twelve months through Dec 2025 was -$3.3 million (up 72.96% YoY), and the annual figure for FY2025 was -$1.2 million, down 247.12%.
  • Gains from Investment Securities for Q4 2025 was -$19000.0 at Collegium Pharmaceutical, roughly flat from -$19000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for COLL hit a ceiling of $3.2 million in Q2 2021 and a floor of -$8.1 million in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $4037.0 (2024), compared with a mean of -$234608.3.
  • Biggest five-year swings in Gains from Investment Securities: soared 2800.55% in 2022 and later tumbled 14414.29% in 2023.
  • Collegium Pharmaceutical's Gains from Investment Securities stood at -$1.1 million in 2021, then surged by 95.1% to -$56000.0 in 2022, then tumbled by 14414.29% to -$8.1 million in 2023, then soared by 64.15% to -$2.9 million in 2024, then surged by 99.35% to -$19000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$19000.0 (Q4 2025), -$19000.0 (Q3 2025), and -$358000.0 (Q2 2025) per Business Quant data.